Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
Status:
NOT_YET_RECRUITING
Trial end date:
2029-10-31
Target enrollment:
Participant gender:
Summary
Treatment with olutasidenib for isocitrate dehydrogenase 1 (IDH1) mutant acute myeloid leukemia (AML) after completion of traditional intensive induction/consolidation is likely to be safe, tolerable, and may provide clinical benefit in terms of maintenance of remission and perhaps improvement in survival.